861841-90-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-aMino-5-(benzyloxy)-2-hydroxyphenyl)ethanone is used as a pharmaceutical compound for its potential opioid-like effects, analgesic, and sedative properties. It is being studied for its potential use in pain management and as a treatment for conditions that may benefit from sedative effects, due to its structural similarity to the alkaloids found in Kratom.
Used in Research and Development:
In the field of scientific research, 1-(3-aMino-5-(benzyloxy)-2-hydroxyphenyl)ethanone serves as a subject of study to better understand its pharmacological profile. Researchers are investigating its mechanism of action, efficacy, and safety to determine its potential applications in medicine and to develop new therapeutic agents based on its chemical structure.

Upstream product

• 861841-94-3 1‐[2-hydroxy-3-nitro-5-(benzyloxy)phenyl]ethanone 
• 100-39-0 benzyl bromide 
• 30992-63-3 5-benzyloxy-2-hydroxyacetophenone 
• 490-78-8 2,5-Dihydroxyacetophenone 

Downstream Products

• 926319-53-1 8-(bromoacetyl)-6-(phenylmethoxy)-2H-1,4-benzoxazin-3(4H)-one 
• 869478-12-6 8-(2R)-oxirane-6-(phenylmethoxy)-2H-1,4-benzoxazine-3(4H)-one 
• 869478-09-1 8-acetyl-6-(phenylmethoxy)-4H-1,4-benzoxazin-3-one 
• 861841-89-6 7-acetyl-5-benzyloxy-3H-benzooxazol-2-one 

Relevant academic research and scientific papers

CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE

The invention provides a class of compounds represented by formula (I), having bifunctional active quaternary ammonium salt structure of a β2-adrenoreceptor agonist and an M receptor antagonist, a pharmaceutically acceptable salt, solvate, and optical isomer thereof. A pharmaceutical composition comprising such a compound with quaternary ammonium salt structure, a method for preparing such a compound with quaternary ammonium salt structure and an intermediate thereof, and uses thereof in treating pulmonary disorders are also provided. The compounds of the invention have high selectivity to the M receptor subtype, and have less adverse reaction and lower toxic and side effects in the treatment of pulmonary diseases such as COPD and asthma.

Preparation method of 1-[2-hydroxy-3-amino-5-(benzyloxy) phenyl]-ethanone

The invention discloses a preparation method of 1-[2-hydroxy-3-amino-5-(benzyloxy) phenyl]-ethanone, which comprises the following steps of: (1) mixing 1-[2-hydroxy-3-nitro-5-(benzyloxy) phenyl]-ethanone (II) in methanol, adding FeCl3/C, heating to 70 DEG

Benzoxazine compound and its preparation methods and application

The invention relates to a benzoxazine compound represented in the following formula 1. The benzoxazine compound can serve as a beta 2 receptor agonist. The formula can be seen from the description.

Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacy

Compound 4p was identified from a series of 6-hydroxy-4H-benzo[1,4]oxazin-3-ones as potent agonist of the human β2-adrenoceptor with a high β1/β2-selectivity. A complete reversal of acetylcholine-induced bronchoconstrictio

PROCESS FOR THE MANUFACTURING OF BETA MIMETICS

The invention relates to a method for producing betamimetics of formula (1), wherein in which n represents 1 or 2; R1 represents hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl; R2 represents hydrogen, halogen, C

Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof

The present invention relates to enantiomerically pure compounds of formula 1 wherein the groups m, n, B, X, R1, m and Ym- may have the meanings given in the claims and specification, methods for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

Medicament Combinations for the Treatment of Respiratory Diseases

The present invention relates to new medicament combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein A, B, R1, X, n and m may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

PROCESS FOR THE MANUFACTURING OF BETAMIMETICS

The present invention relates to a process for preparing betamimetics of formula 1, wherein n denotes 1 or 2; R1 denotes hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl; R2 denotes hydrogen, halogen, C1-4/su

New betamimetics for the treatment of respiratory complaints

The present invention relates to compounds of formula 1 wherein the groups n, m, B, X and R1 may have the meanings given in the claims and specification, processes for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments

The present invention relates to enantiomerically pure compounds of general formula 1 wherein the groups R1, R2, R3, R4 and X? may have the meanings given in the claims and in the specification, proce